Material Safety Data Sheet Section 1. Identification of the substance Product Name: 4-Bromo-3-methoxybenzamide Synonyms: Section 2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. Section 3. Composition/information on ingredients. Ingredient name: 4-Bromo-3-methoxybenzamide CAS number: 176961-57-2 Section 4. First aid measures Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section 5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section 6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution: Wear approved mask/respirator Hand precaution: Wear suitable gloves/gauntlets Skin protection: Wear suitable protective clothing Eye protection: Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section 7. Handling and storage Handling: This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Store in closed vessels. Storage: Section 8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section 9. Physical and chemical properties Appearance: Not specified Boiling point: No data No data Melting point: Flash point: No data Density: No data Molecular formula: C8H8BrNO2 Molecular weight: 230.1 Section 10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide. Section 11. Toxicological information No data. Section 12. Ecological information No data. Section 13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section 14. Transportation information Non-harzardous for air and ground transportation. Section 15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313.
Compounds of the formula I:
or pharmaceutically acceptable salts thereof,
wherein R
1
, R
2
, R
3
and R
4
are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).
[EN] METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE TRIAZOLOPYRIDINES SUBSTITUÉES
申请人:BAYER PHARMA AG
公开号:WO2014009219A1
公开(公告)日:2014-01-16
The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.
METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES
申请人:BAYER PHARMA AKTIENGESELLSCHAFT
公开号:US20150148542A1
公开(公告)日:2015-05-28
The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.
[EN] STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES<br/>[FR] INHIBITEURS STK4 POUR LE TRAITEMENT DE MALIGNITÉS HÉMATOLOGIQUES
申请人:DANA FARBER CANCER INST INC
公开号:WO2016161145A1
公开(公告)日:2016-10-06
The application relates to compounds of Formula (I'): which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.
[EN] TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] DÉRIVÉS DU TRIAZOLE POUR TRAITEMENT DE LA MALADIE D'ALZHEIMER
申请人:MERCK SHARP & DOHME
公开号:WO2010071741A1
公开(公告)日:2010-06-24
According to the invention there is provided a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof; wherein the variables are as defined herein. The compounds selectively attenuate the production of Aß42 and hence are useful in treatment of Alzheimer's disease and related conditions.